325 related articles for article (PubMed ID: 18387054)
1. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Yuan Y; Iloeje U; Li H; Hay J; Yao GB
Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
5. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B].
Calcagno JI; Augustovski F; Gadano A; Souto A; Yuan Y
Acta Gastroenterol Latinoam; 2008 Dec; 38(4):260-73. PubMed ID: 19157381
[TBL] [Abstract][Full Text] [Related]
8. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Almeida AM; Silva AL; Brandão CM; Cherchiglia ML; Andrade EI; Araújo de Oliveira GL; Carmo RA; Acurcio Fde A
Rev Saude Publica; 2012 Dec; 46(6):942-9. PubMed ID: 23503535
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
Costa AM; L 'italien G; Nita ME; Araujo ES
Braz J Infect Dis; 2008 Oct; 12(5):368-73. PubMed ID: 19219274
[TBL] [Abstract][Full Text] [Related]
12. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
13. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
[TBL] [Abstract][Full Text] [Related]
15. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Buti M; Brosa M; Casado MA; Rueda M; Esteban R
J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
20. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
